List view / Grid view
20 April 2015 | By Victoria White
The first presentation of data investigating the use of KEYTRUDA in 25 patients with advanced pleural mesothelioma was made at AACR 2015...
14 April 2015 | By Victoria White
A new liver cancer treatment developed by the UMC Utrecht that uses uses radioactive holmium microspheres has received the European CE mark...
9 April 2015 | By Victoria White
INO-3112 DNA immunotherapy has generated strong T cell responses in patients with head and neck cancer associated with human papillomavirus (HPV)...
9 April 2015 | By Victoria White
Exelixis has announced that the FDA has granted Fast Track designation to cabozantinib for treatment of patients with advanced renal cell carcinoma...
8 April 2015 | By Victoria White
Advaxis and Merck have initiated enrollment in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA and KEYTRUDA in patients with mCRPC...
8 April 2015 | By Victoria White
Lion Biotechnologies has announced that data from a study of metastatic cervical cancer patients treated with treated with HPV-TIL has been published...
26 March 2015 | By Victoria White
Apceth has announced the successful completion of the Phase I and initiation of the Phase II with the engineered cell therapy product Agenmestencel-T...
10 March 2015 | By Michael Weichel, Kristina Ellwanger, Ivica Fucek, Stefan H.J. Knackmuss, Erich Rajkovic, Uwe Reusch, Claudia Wall, and Eugene A. Zhukovsky, Affimed Therapeutics AG
The bi-specific antibody format is becoming the preferred antibody modality for current development projects in the pharmaceutical industry. This is due to an unsurpassed increase in functional activity relative to traditional mono-specific monoclonal antibodies, and a breakthrough in manufacturability enabled by novel designs. One such bi-specific format, the TandAb, produces…
19 February 2014 | By Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent
Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent answers the question: "Other than oncology, for which disease areas do you see Antibody Drug Conjugates (ADC) being used extensively in the future?"
25 February 2013 | By Esther P. Black, College of Pharmacy and Markey Cancer Center, University of Kentucky
Cancer treatment faces a conundrum: a growing lack of therapeutics with lasting effects. The low hanging fruit of the medicinal chemistry orchard seems to have been picked, and modification of existing anti-cancer therapeutics has produced only incremental rewards[1]. Thus, both pharmaceutical companies and academic researchers are left searching for new…
